Loading
NASDAQHealthcareBiotechnology
Latest quote
$30.06
+$2.06 · +7.36%
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Previous close
$30.06
+$2.06 · +7.36%
Regular session · ET · Market data may be delayed.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Day range
Current $30.06
52-week range
Current $30.06
Regular session · ET · Market data may be delayed.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Day range
Current $30.06
52-week range
Current $30.06
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$43.75
45.54% upsidePrice history unavailable
High $50.00Average $43.75Low $40.00Limited analyst sample: 3 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM37.82M0.05%79.88B USD0.19%$296.01+0.28%
State Street SPDR S&P Biotech ETFXBI21.35M0.19%11.49B USD0.35%$163.81-0.35%
iShares Russell 2000 Growth ETFIWO9.49M0.07%14.58B USD0.24%$377.54+0.12%
Vanguard Russell 2000 ETFVTWO8.69M0.05%17.4B USD0.06%$119.62+0.25%
Vanguard Extended Market ETFVXF6.17M0.01%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Value ETFIWN4.3M0.03%14.47B USD0.24%$224.62+0.40%
Vanguard Russell 2000 Growth ETFVTWG1.15M0.07%1.7B USD0.06%$275.67+0.20%
Fidelity Fundamental Small-Mid Cap ETFFFSM1.07M0.07%1.5B USD0.43%$36.48+0.63%iShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 Growth ETFVTWGFidelity Fundamental Small-Mid Cap ETFFFSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
